- Presentation available September 11, 2023 on BGBIO website -

BERGEN, Norway, September 11, 2023 - BerGenBio ASA (OSE: BGBIO), a clinical
-stage biopharmaceutical company developing novel, selective AXL kinase
inhibitors for Non-Small Cell Lung Cancer (NSCLC), announcedtoday that the
Company will participate in the H.C. Wainwright 25th Annual Global Investment
Conference held in New York City, September 11-13, 2023.

Chief Executive Officer Martin Olin will provide an update on BerGenBio
including a review of clinical data substantiating the role of selective AXL
inhibition with its lead molecule bemcentinib in cancer and describing on-going
activities in the treatment of first line metastatic NSCLC patients with STK11
mutations - a known prognostic factor in poorer response to current standard of
care therapies.

The presentation used in the webcast will be uploaded to the investor section of
the Company's websitewww.bergenbio.com/investors/presentations at time of
presentation, September 11, 7.00am ET (13:00 CEST).

-End-

Contacts

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including cancer and severe respiratory infections. The
Company is focused on its proprietary lead candidate, bemcentinib, a potentially
first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC
and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com.

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties, and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.